NRx Pharmaceuticals
@NRxPharma
Followers
2,505
Following
214
Media
217
Statuses
1,067
We draw upon decades of collective, scientific, & drug-development experience to address very high unmet needs of patients and bring improved health to patients
Wilmington, DE
Joined June 2016
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Cheney
• 502132 Tweets
Michigan
• 179111 Tweets
England
• 140983 Tweets
Ireland
• 120349 Tweets
Lookman
• 40429 Tweets
Grealish
• 30130 Tweets
Arkansas
• 27353 Tweets
Big House
• 24969 Tweets
#MustafaKamalinAskerleriyiz
• 23885 Tweets
Super Eagles
• 20541 Tweets
PLANETARIO FURIOSO
• 19499 Tweets
Lee Carsley
• 18345 Tweets
Penn State
• 15909 Tweets
Ann Arbor
• 15182 Tweets
Ewers
• 10758 Tweets
Pedro Almodóvar
• 10640 Tweets
1
20
119
NRx has validated the first commercial formulation of its medicine for Critical
#COVID
-19, allowing for high volume manufacture, as potential regulatory approvals are obtained. Read more in the press release here:
9
31
109
Today we announced having met the target enrollment of 165 patients in our Phase 2b/3
#clinicaltrial
of aviptadil (
#RLF100
) for Critical
#COVID19
.
Read the press release:
4
22
107
Today we shared additional data on ZYESAMI™ (aviptadil) showing a 10 day accelerated recovery from respiratory failure among patients with Critical
#COVID19
treated with high flow nasal oxygen.
Learn more:
12
41
108
.
@CDCgov
has reported over 300,000 new
#COVID19
cases in the last 7 days. With cases on the rise, the need for effective treatments is greatly emphasized.
Follow our journey at
More COVID-19 stats from the CDC:
#aviptadil
8
56
106
Aviptadil (
#RLF100
) is thought to protect against Critical
#COVID19
by binding to the Alveolar Type II lung cells that are targeted by
#SARSCoV2
.
Learn more about the MOA and follow our journey at
#aviptadil
7
46
101
Yesterday, the Data Monitoring Committee (DMC) voted unanimously that our study of
#aviptadil
(RLF-100™) in Critical
#COVID
-19 patients should continue as planned. Follow our journey at
Read more:
19
29
99
Today we announced the submission of our request for Emergency Use Authorization for aviptadil (
#RLF100
) in patients with Critical COVID-19 who who have exhausted all approved treatments:
Follow our journey:
8
40
94
NRx completed phase 2b/3 data analysis of ZYESAMI™ for
#COVID19
respiratory failure treatment. Investor call on 3/29 @ 8:30am EDT. Dial 866-373-3402 or webcast @
#aviptadil
#ZYESAMI
#pandemic
#SARSCoV2
#coronavirus
#biotech
12
31
99
Listen to our 3/29 investor call on ZYESAMI™ demonstrating significant benefit in critical
#COVID19
survival and meeting the primary endpoint of phase 2b/3 clinical trial:
#aviptadil
#ZYESAMI
#pandemic
#SARSCoV2
#coronavirus
#biotechnews
#financialnews
5
29
94
We are pleased to announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial which will allow us to gather data on the use of inhaled aviptadil for Critical
#COVID19
.
Learn more:
2
31
96
Yesterday we announced our request for an Emergency Use Authorization from the FDA for the use of
#RLF100
(aviptadil). Read more about it from
@PHLBizJGeorge
via
@PHLBizJournal
.
4
33
92
“For the most part, people who die of
#COVID
die of respiratory distress. So we’ve developed a drug that specifically attacks that mechanism by which COVID kills people.” See Dr. Javitt,
#NeuroRx
CEO, discuss
#ZYESAMI
on
#FoxBusiness
.
#clamancountdown
11
34
91
Our CEO Dr. Jonathan Javitt recently sat down with
@RfwrightLSL
of Life Science Leader and a panel of biopharma CEOs including
@PeterDiamandis
to discuss
#COVID19
technologies in development and our work with
#RLF100
.
Watch the roundtable:
4
32
86
ZYESAMI™ is the first medicine to show efficacy in a randomized, double-blind, multicenter trial, achieving more instances of recovery in critically ill
#COVID
-19 patients with respiratory failure, compared to placebo.
6
31
90
CEO Dr. Jonathan Javitt shared the story of ZYESAMI™ (aviptadil) and its journey from deep storage to
#ClinicalTrials
for Critical
#COVID19
with Moira Gunn of
@NPR
's
@BiotechNation
.
Listen now:
4
24
84
“We look forward to working with the FDA in hopes of providing critically ill patients with a new medicine that will increase their chances of recovery, enabling them to leave the hospital and return to their families significantly sooner.” - Jonathan Javitt, MD CEO of NRx
4
19
92
Today we announced the completion of our agreement with Relief Therapeutics covering the global commercialization of Aviptadil. NeuroRx is leading the commercialization in the US, Canada & Israel, and Relief in Europe and the rest of the world.
6
29
85
CEO Dr. Jonathan Javitt recently sat down with
@Jerusalem_Post
to discuss our progress with aviptadil (
#RLF100
) and NeuroRx’s unique history and culture.
Learn more about our journey:
5
30
83
NRx Pharmaceuticals has submitted an application to the FDA requesting Emergency Use Authorization for ZYESAMI™ (Aviptadil-acetate) to treat Critically Ill COVID-19 patients suffering respiratory failure. Learn more at:
4
23
84
Worldwide, about 500,000 new cases of COVID-19 are confirmed daily. NRx is working to help the sickest of
#COVID
-19 patients recover.
10
25
85
We have established supply chain agreements and ordered Aviptadil (
#RLF100
) drug substance to potentially treat 1 million patients with
#COVID19
, should the pandemic continue and our studies prove successful.
Learn more:
#aviptadil
8
31
80
NeuroRx CEO Dr. Jonathan Javitt and COO & Head of Operations Robert Besthof recently sat down with
@MoeAlsumidaie
of
@Clin_Trials
to discuss the challenges of developing
#COVID19
therapies and our work with ZYESAMI™ (previously RLF-100™: aviptadil):
3
30
78
Gain scientific insight into the mechanisms that underlie our investigational drug
#Aviptadil
(
#RLF100
) and its potential to treat critical
#COVID19
and other life-threatening pulmonary conditions.
Read the pre-print on
@Authorea
:
1
29
76
Our team excels at rapid advancement of already-known molecules as potentially lifesaving solutions.
#Aviptadil
(
#RLF100
) went from an idea in March to drug on-site in mid May 2020.
Learn more and follow us:
9
21
77
NRx announces positive data results from the ZYESAMI™ Expanded Access Protocol. Read more:
#COVID19
12
16
74
Dr. Fauci highlighted ZYESAMI's new clinical trial with
@NIH
in Friday's briefing from the White House coronavirus task force.
ICYMI: ZYESAMI will be studied alone and in combination with remdesivir for treating severely ill COVID patients.
13
24
77
NRx Pharmaceuticals announced a new partnership that has the best for patients in mind. Click here to read our press release about efforts to develop an inhaler for respiratory conditions.
9
22
76
Today we announced a feasibility collaboration with
@TFFPharma
in order to identify an optimal long-term stable formulation of ZYESAMI™ for
#COVID19
.
Learn more:
12
19
72
7
14
70
The
@BioRender
#COVID19
Vaccine & Therapeutics tracker features the development progress of COVID-19 therapeutics and an activity feed with live updates on their advancements.
Check out our drug in development, aviptadil (
#RLF100
):
6
18
68
Our CEO Dr. Jonathan Javitt spoke with
@RfwrightLSL
about how we turned a 10-year-old drug into a promising drug in development for the treatment of critical
#COVID19
in just 10 weeks.
Watch now on Life Science Leader:
#RLF100
#aviptadil
7
29
68
🔊 NeuroRx CEO Dr. Jonathan Javitt discussed vaccine rollouts, COVID therapeutics and more on
@Cheddar
!
"Unless we're vigilant to also develop COVID therapeutics; unless we have a way to decrease the lethal effects of COVID, just vaccinating everybody is not going to be enough."
10
21
68
At NeuroRx, we pride ourselves on our ability to be nimble as an organization and rapidly shift our focus to areas of the utmost need. We went from concept to clinic in 10 weeks for our Critical
#COVID19
study of aviptadil.
Learn more about our values:
7
26
62
Dr. Jonathan Javitt, CEO of
#NeuroRx
, joined Yahoo! Finance Live to discuss vaccine concerns,
#ZYESAMI
, EUA and more.
#aviptadil
#pandemic
#SARSCoV2
#coronavirus
#biotechnews
#financialnews
#covidvaccine
#yahoofinance
#drugdevelopment
3
18
64
Tune in to the Disease Control and Prevention Summit today at 10:10 am EST and hear Dr. Jonathan Javitt present new data regarding aviptadil's impact on the "cytokine storm" in patients suffering
#COVID19
. Watch live here:
1
12
65
#ICYMI
– CEO Dr. Jonathan Javitt spoke with
@EdClinical
about our company history and the story of our development of aviptadil (
#RLF100
) for Critical
#COVID19
.
Read the full article in
@ClinicalLeader1
:
3
9
62
#ICYMI
- Get industry insights and learn about our
#ClinicalTrial
approach for ZYESAMI™ (
#RLF100
, Aviptadil) from our executives in
@Clin_Trials
.
More from
@MoeAlsumidaie
:
1
20
61
NRx Pharmaceuticals, Inc. (NRx) is now a public company, trading as NRXP on the
@Nasdaq
Global Select Exchange. We invite you to learn more about our efforts here:
#nasdaq
#MarketNews
4
15
59
CEO Dr. Jonathan Javitt looks ahead to one of biopharma’s biggest challenges in
#2021
: tackling the
#COVID19
pandemic.
Read more industry insight from Dr. Javitt and other biopharma executives in
@PharmaScrip
:
4
16
57
Hundreds of Americans and thousands around the world are dying from COVID-19, many from respiratory failure. Medicines are urgently needed. Newly-formed $NRXP is focused on bringing first in class medicines to patients struggling to take a breath.
#COVID19
2
15
59
Tune in to the Disease Control and Prevention Summit on July 21st at 10:10 am EST to see and hear CEO of NRx, Dr. Jonathan Javitt present new data regarding aviptadil's impact on the "cytokine storm" in patients suffering
#COVID19
. Watch here:
2
14
58
.
@NeuroRxPharma
is excited to announce a new clinical trial of ZYESAMI for the treatment of severely ill COVID-19 patients with Acute Respiratory Distress Syndrome. ZYESAMI will be evaluated alone and in combination with remdesivir.
15
10
57
NeuroRx Pharma CEO Dr. Jonathan Javitt recently spoke with industry veterans
@AlokTayi
and
@RahulC
about our development of ZYESAMI™ (
#RLF100
, aviptadil) on the
@Biotech2050Pod
podcast.
Listen now:
5
16
57
CEO Dr. Jonathan Javitt spoke with
@BioSpace
about the recently announced Phase 2b/3 data for ZYESAMI™ (
#aviptadil
) and how we will continue to advance the development of our investigational
#COVID19
drug.
Read it here:
4
19
56
CEO Dr. Jonathan Javitt recently sat down with
@EdClinical
of
@ClinicalLeader1
to discuss NeuroRx’s unique history and how our culture helps us accelerate the development of much needed therapies.
Learn more:
4
9
54
Today we announced that our CEO Dr. Jonathan Javitt will present a company overview at the
@SoleburyTrout
Fall Private Company Showcase.
Join us tomorrow at 9 AM ET:
Read the press release:
3
16
50
CEO Dr. Jonathan Javitt recently sat down with
@BioPharmaMike
on
@DRGInsights
’ “Conversations in Healthcare” series to discuss our overall plans for aviptadil (
#RLF100
) and some data of patients in our Expanded Access (open label) study.
Watch now:
12
17
51
The Georgian Ministry of Health today agreed to an expanded access program for ZYESAMI.
We're eager to deliver this lifesaving drug to critically ill COVID-19 patients in Georgia, the Caucasus region and beyond.
Learn more:
14
11
55
CEO Dr. Jonathan Javitt spoke with
@NBCLA
about our recent partnership with
@UCIrvineHealth
for the initiation of our Phase 2/3
#ClinicalTrial
with the inhaled formulation of ZYESAMI™ (
#RLF100
, aviptadil) for Severe
#COVID19
.
Watch now:
5
12
53
CEO Dr. Jonathan Javitt recently sat down with
@thequeenmuse1
of
@phillymag
to discuss NeuroRx’s unique history, our focus on the development of drugs for some of the most severe conditions, and our roots in the greater Philadelphia area.
Learn more:
5
10
50
Vaccines for COVID-19 are crucial, but they are only part of the solution. Medicines to help
#COVID
patients recover from this virus are very much in need. Follow NRx to learn how we are addressing unmet needs in treating COVID-19.
8
15
51
“As variants continue to evolve, the likelihood that some will bypass the vaccine and create another surge, tells us that the need for therapeutics remains high.” - Dr. Jonathan Javitt, MD CEO of NRx on the need for more medicines to treat
#COVID
-19.
2
12
51
For all those celebrating this holiday season, we wish you a safe, healthy and happy holidays.
Follow our journey at
4
2
47
This week is Respiratory Care Week, an important week of advocating for patients and supporting
#RespiratoryTherapists
. In the midst of
#COVID19
, respiratory care is more vital than ever.
Learn how you can get involved in
#RCWeek20
from
@AARC_tweets
:
2
14
49
#COVID19
has also had an impact on mental health across the world. Through our development of ZYESAMI (
#RLF100
) for Critical COVID-19 and NRX-100/101 for bipolar
#depression
, we have programs focused on two of the highest unmet medical needs.
More:
3
15
48
Learn more about our development of ZYESAMI (Aviptadil,
#RLF
-100) for Critical
#COVID19
, our clinical programs, and merger with Big Rock Acquisition Corp. in
@GENBio
.
More from
@AlexWestchester
:
0
22
49
NRx Chairman and CEO Jonathan Javitt will be speaking at the
@LongwoodFund
Healthcare Leaders web con Oct 4-5 with fellow biopharma CEOs, the Head of the FDA, Gov Baker, and top academics.
You can join the meeting here:
#longwoodhealthcareleaders
12
14
47
NRx Pharmaceuticals defies the traditional pharma industry paradigm. Our scientific expertise lets us move rapidly to research and develop already-known molecules and deliver lifesaving solutions.
2
13
49
Today we reported Initial Phase 2b/3 study results for ZYESAMI™ (aviptadil) in patients with respiratory failure due to critical
#COVID19
.
Learn more:
17
18
48
ICYMI: Our CEO, Dr. Jonathan Javitt joined
@i24NEWS
to discuss the ongoing
#Aviptadil
trial in
#COVID19
. Watch:
#ARDS
#RLF100
4
12
47
“It’s a 65-million-year-old molecule that's seeing its first shot in a randomized controlled trial.” NRx CEO, Dr. Jonathan Javitt on Bloomberg Radio yesterday announcing NRx as a publicly traded company, highlighting ZYESAMI and NRx-101 trials and more.
6
10
46
From suicidal depression to Critical
#COVID19
, we have always focused on patients with the highest unmet need.
Watch CEO Dr. Jonathan Javitt explain the origins of NeuroRx on
@DRGInsights
’ “Conversations in Healthcare” with
@BioPharmaMike
:
8
15
43
We are excited about our plan to merge with Big Rock Partners Acquisition Corp., a critical part of our journey to develop treatments for patients with very high unmet needs.
Learn more about our plan of merger:
1
13
45
NeuroRx’s culture of dedication and urgency uniquely positions us to develop much needed therapies in areas of very high unmet need, including critical
#COVID19
. Watch our CEO Dr. Jonathan Javitt discuss the hurdles we are overcoming to develop Aviptadil:
0
10
38
RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells
4
13
41
Learn more about our recent Agreement and Plan of
#Merger
with Big Rock Partners Acquisition Corp. from
@PHLBizJGeorge
in
@PHLBizJournal
.
Read:
5
8
37
NRx Pharmaceuticals is dedicated to our mission of “Bringing Hope to Life” through development of innovative medicines for life-threatening, unmet medical needs.
By creating therapies where none exist, we put the patient at the center of everything we do.
0
6
40
NRx extends its ongoing Phase 2/3 trial of inhaled ZYESAMI™ to Nation of Georgia, in partnership with Denk Pharma (Georgia), and Cromos, LLC.
See full details at:
#COVID19
3
10
36
The need for innovative new medicines will always be necessary, as doctors treating COVID-19 patients need effective remedies to save lives.
#COVID19
2
6
33
Physicians in the Nation of Georgia will be trained in emergency use of intravenous ZYESAMI™ for patients suffering Critical COVID-19.
See the full press release here:
#COVID19
2
10
32
🔊 NeuroRx CEO
@Jjgmail
reconnected with Moira Gunn on NPR's
@biotechnation
to share an update about ZYESAMI's clinical trials.
3
10
29
This trial will be carried out across the country in partnership with
@NIAIDNews
and
@nih_nhlbi
, as part of
@NIH
's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) research agenda. For more information:
2
3
28
NRx Pharmaceuticals announces a new partnership in the fight against COVID - Read the full Press Release here:
#COVID19
1
7
25
There are no approved medicines to treat people with bipolar disorder. NRx Pharmaceuticals is developing the first investigational medicines for this acute mental illness. Follow us to stay informed.
#MentalHealthAwarenessMonth
9
5
25
NRx's Zyesami® (Aviptadil) is now the only drug left in the ACTIV-3 NIH program -
#zyesami
#aviptadil
#covid19
#pharmaceuticals
#data
#NRX
#NRXP
#ACTIV3
#pharmanews
#clinicaltrials
#medicine
#covid
0
3
23
NRx Pharmaceuticals, Inc. today announced that it has filed a new Breakthrough Therapy designation request with the FDA focused on a subgroup of patients with Critical COVID-19 that in addition to aviptadil or placebo were also treated with remdesivir.
0
4
21
Recent Publication regarding the use of Zyesami™
Source -
#Aviptadil
#Covid
#FDA
#NRXP
#Omicron
#RightToTry
#ZYESAMI
#pharmaceuticals
#NRX
#ClinicalTrials
0
7
20